K Rahbar1, M Boegemann2, A Yordanova3, M Eveslage4, M Schäfers5, M Essler3, H Ahmadzadehfar3. 1. Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany. rahbar@uni-muenster.de. 2. Department of Urology, University Hospital Muenster, Muenster, Germany. 3. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. 4. Institute of Biostatistics and Clinical Research, University Hospital Muenster, Muenster, Germany. 5. Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.
Abstract
AIM: Our aim was to evaluate overall survival and parameters prognosticating longer survival in a large and homogeneous group of patients treated with 177Lu-PSMA-617 radioligand therapy with heavily pretreated advanced metastatic castration resistant prostate cancer. METHODS: A total of 104 patients were treated with 351 cycles of 177Lu-PSMA-617. Prostate specific antigen (PSA) changes after the first cycle of therapy were documented prior to a second cycle. Patients were followed-up for overall survival (OS). Any PSA decline, PSA decline ≥50%, initial PSA, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), visceral metastases and cumulative injected activity were analyzed and evaluated according to OS. Multivariable analysis with parameters with a p-value ≤0.05 in univariate analysis was performed, additionally adjusting for age and presence of visceral metastases. RESULTS: A total of 51 patients (49%) died during the observation period. The majority of patients (97%) presented with bone metastases, 77% with lymph node metastases and 32% with visceral metastases. All patients were treated with at least one line of chemotherapy. Either abiraterone or enzalutamide had been given in 100% of the patients. Any PSA decline occurred in 70 (67%) and a PSA decline ≥50% in 34 (33%) of patients after the first cycle. The median OS was 56.0 weeks (95%CI: 50.5-61.5). Initial PSA decline ≥50%, initial LDH, visceral metastases, second line chemotherapy or prior radium-223 did not have an effect on survival, whereas any initial PSA decline, initial ALP <220 U/L and cumulative injected activity ≥18.8 GBq were associated with a longer survival. A step-by-step analysis revealed a PSA decline ≥20.87% as the most noticeable cut-off prognosticating longer survival, which remained an independent prognosticator of improved OS in the multivariate analysis. CONCLUSION: 177Lu-PSMA-617 RLT is a new effective therapeutic and seems to prolong survival in patients with advanced mCRPC pretreated with chemotherapy, abiraterone and/or enzalutamide.
AIM: Our aim was to evaluate overall survival and parameters prognosticating longer survival in a large and homogeneous group of patients treated with 177Lu-PSMA-617 radioligand therapy with heavily pretreated advanced metastatic castration resistant prostate cancer. METHODS: A total of 104 patients were treated with 351 cycles of 177Lu-PSMA-617. Prostate specific antigen (PSA) changes after the first cycle of therapy were documented prior to a second cycle. Patients were followed-up for overall survival (OS). Any PSA decline, PSA decline ≥50%, initial PSA, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), visceral metastases and cumulative injected activity were analyzed and evaluated according to OS. Multivariable analysis with parameters with a p-value ≤0.05 in univariate analysis was performed, additionally adjusting for age and presence of visceral metastases. RESULTS: A total of 51 patients (49%) died during the observation period. The majority of patients (97%) presented with bone metastases, 77% with lymph node metastases and 32% with visceral metastases. All patients were treated with at least one line of chemotherapy. Either abiraterone or enzalutamide had been given in 100% of the patients. Any PSA decline occurred in 70 (67%) and a PSA decline ≥50% in 34 (33%) of patients after the first cycle. The median OS was 56.0 weeks (95%CI: 50.5-61.5). Initial PSA decline ≥50%, initial LDH, visceral metastases, second line chemotherapy or prior radium-223 did not have an effect on survival, whereas any initial PSA decline, initial ALP <220 U/L and cumulative injected activity ≥18.8 GBq were associated with a longer survival. A step-by-step analysis revealed a PSA decline ≥20.87% as the most noticeable cut-off prognosticating longer survival, which remained an independent prognosticator of improved OS in the multivariate analysis. CONCLUSION: 177Lu-PSMA-617 RLT is a new effective therapeutic and seems to prolong survival in patients with advanced mCRPC pretreated with chemotherapy, abiraterone and/or enzalutamide.
Authors: Kambiz Rahbar; Matthias Schmidt; Alexander Heinzel; Elisabeth Eppard; Axel Bode; Anna Yordanova; Michael Claesener; Hojjat Ahmadzadehfar Journal: J Nucl Med Date: 2016-04-07 Impact factor: 10.057
Authors: Matthew Smith; Johann De Bono; Cora Sternberg; Sylvestre Le Moulec; Stéphane Oudard; Ugo De Giorgi; Michael Krainer; Andries Bergman; Wolfgang Hoelzer; Ronald De Wit; Martin Bögemann; Fred Saad; Giorgio Cruciani; Antoine Thiery-Vuillemin; Susan Feyerabend; Kurt Miller; Nadine Houédé; Syed Hussain; Elaine Lam; Jonathan Polikoff; Arnulf Stenzl; Paul Mainwaring; David Ramies; Colin Hessel; Aaron Weitzman; Karim Fizazi Journal: J Clin Oncol Date: 2016-07-11 Impact factor: 44.544
Authors: Axel Bräuer; Lena Sophie Grubert; Wolfgang Roll; Andres Jan Schrader; Michael Schäfers; Martin Bögemann; Kambiz Rahbar Journal: Eur J Nucl Med Mol Imaging Date: 2017-06-17 Impact factor: 9.236
Authors: Kambiz Rahbar; Axel Bode; Matthias Weckesser; Nemanja Avramovic; Michael Claesener; Lars Stegger; Martin Bögemann Journal: Clin Nucl Med Date: 2016-07 Impact factor: 7.794
Authors: Kambiz Rahbar; Hojjat Ahmadzadehfar; Clemens Kratochwil; Uwe Haberkorn; Michael Schäfers; Markus Essler; Richard P Baum; Harshad R Kulkarni; Matthias Schmidt; Alexander Drzezga; Peter Bartenstein; Andreas Pfestroff; Markus Luster; Ulf Lützen; Marlies Marx; Vikas Prasad; Winfried Brenner; Alexander Heinzel; Felix M Mottaghy; Juri Ruf; Philipp Tobias Meyer; Martin Heuschkel; Maria Eveslage; Martin Bögemann; Wolfgang Peter Fendler; Bernd Joachim Krause Journal: J Nucl Med Date: 2016-10-20 Impact factor: 10.057
Authors: Hojjat Ahmadzadehfar; Kambiz Rahbar; Stefan Kürpig; Martin Bögemann; Michael Claesener; Elisabeth Eppard; Florian Gärtner; Sebastian Rogenhofer; Michael Schäfers; Markus Essler Journal: EJNMMI Res Date: 2015-06-20 Impact factor: 3.138
Authors: Hojjat Ahmadzadehfar; Stefanie Zimbelmann; Anna Yordanova; Rolf Fimmers; Stefan Kürpig; Elisabeth Eppard; Florian C Gaertner; Xiao Wei; Stefan Hauser; Markus Essler Journal: Oncotarget Date: 2017-02-25
Authors: Wolfgang P Fendler; Svenja Reinhardt; Harun Ilhan; Andreas Delker; Guido Böning; Franz J Gildehaus; Christian Stief; Peter Bartenstein; Christian Gratzke; Sebastian Lehner; Axel Rominger Journal: Oncotarget Date: 2017-01-10
Authors: Ken Herrmann; Markus Schwaiger; Jason S Lewis; Stephen B Solomon; Barbara J McNeil; Michael Baumann; Sanjiv S Gambhir; Hedvig Hricak; Ralph Weissleder Journal: Lancet Oncol Date: 2020-03 Impact factor: 41.316
Authors: Clemens Kratochwil; Wolfgang Peter Fendler; Matthias Eiber; Richard Baum; Murat Fani Bozkurt; Johannes Czernin; Roberto C Delgado Bolton; Samer Ezziddin; Flavio Forrer; Rodney J Hicks; Thomas A Hope; Levant Kabasakal; Mark Konijnenberg; Klaus Kopka; Michael Lassmann; Felix M Mottaghy; Wim Oyen; Kambiz Rahbar; Heiko Schöder; Irene Virgolini; Hans-Jürgen Wester; Lisa Bodei; Stefano Fanti; Uwe Haberkorn; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-22 Impact factor: 9.236
Authors: H Ahmadzadehfar; P Albers; A Bockisch; M Boegemann; C Böhme; W Burchert; M Dietlein; A Drzezga; U Fabry; G Feldmann; A Heidenreich; A Heinzel; K Herrmann; A Heyll; C Höhling; C Kreuzer; D Laufer; R Mengel; F M Mottaghy; H-W Müller; S C Müller; E Ost; K Rahbar; W Reifenhäuser; M Schäfers; C Schlenkhoff; M Schmidt; I Schmidt-Wolf; C Wildenhain; B Zimmer; M Essler Journal: Urologe A Date: 2018-06 Impact factor: 0.639
Authors: Mohammad S Sadaghiani; Sara Sheikhbahaei; Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Lilja B Solnes; Michael A Gorin; Nae-Yuh Wang; Steven P Rowe Journal: Eur Urol Date: 2021-04-08 Impact factor: 20.096
Authors: Hojjat Ahmadzadehfar; Ralf Matern; Richard P Baum; Robert Seifert; Katharina Kessel; Martin Bögemann; Clemens Kratochwil; Hendrik Rathke; Harun Ilhan; Hanna Svirydenka; Mike Sathekge; Levent Kabasakal; Anna Yordanova; Francisco Osvaldo Garcia-Perez; Kalevi Kairemo; Masha Maharaj; Diana Paez; Irene Virgolini; Kambiz Rahbar Journal: Eur J Nucl Med Mol Imaging Date: 2021-05-25 Impact factor: 9.236